Addictive BehaviorsNovember 1, 2025Samantha M Ross-Cypcar, Justin A Haegele, Jeanette M Garcia
While recent nationally representative studies have evaluated the association between hallucinogen use and mental health events, little is known about these associations among disabled adults. Our primary aim was to use national data from the 2021, 2022, and 2023 National Survey on Drug Use and Health (NSDUH) to determine how past-year use of specific hallucinogens is associated with disabled...
The global prevalence of depression is high, and there are concerns about the therapeutic effectiveness of current treatments. Research over the past two decades has led to a new class of alternative treatments termed 'psychedelic-assisted therapy (PAT).' This study aimed to investigate the attitudes toward the application and use of psychedelic-assisted therapies in the United Kingdom...
Twice‐weekly dosing of intranasal esketamine resulted in significant improvement in depressive symptoms compared with placebo in adults with treatment‐resistant depression, a 4‐week trial has found. Esketamine doses of 56 and 84 mg both outperformed placebo in the post‐marketing trial. Study results were published online July 2, 2025, in JAMA Psychiatry.
Abstract Background Behavioural studies in animal models represent a critical component of psychiatric drug development. Positive results in animal studies have identified novel therapeutic targets for major depressive disorder (MDD) but efficacy in humans has largely not been borne out in clinical trials. A possible reason for this failed translation is inappropriate dose selection and the...
Wissenschaftler*innen der polnischen LUXMED Gruppe bewerteten mit einer Metaanalyse die Wirksamkeit und Sicherheit von Psilocybin bei der Behandlung von Major Depressionen (MDD), um die optimale Dosis und den optimalen Zeitpunkt für klinische Studien zu bestimmen.
Psycho-OncologyNovember 1, 2025Marie-Estelle Gaignard, Dominica Martin, Jelena Stanic et al.
Mindfulness-Based Interventions (MBIs) are recognized as beneficial in oncology supportive care. While qualitative analyses of mindfulness program experiences exist, this is the first mixed methods study to examine patients' experiences after participating in the online Mindfulness-Based Cancer Recovery (e-MBCR) program. The SERENITY study was a pilot randomized controlled trial evaluating the...
Although research shows that psychedelic use may lead to improvement in mental health and well-being, the underlying changes in psychological predictors associated with these improvements remain unclear. 161 participants were recruited in a prospective online survey assessing naturalistic psychedelic use. We used lasso regression to assess how 19 distinct changes in psychological variables...
Mushrooms of the Amanita genus are considered among the most toxic, causing severe poisoning, often resulting in death. However, of the 707 described species within this genus, only around a dozen contain the toxic octapeptides classified as amanitotoxins and phallotoxins. While most representatives of the genus are considered inedible species, there are a few exceptions that are palatable...
Translational PsychiatryOctober 31, 2025Kristin L Dawson, Athena May Jean M. Carangan, Jessica Klunder et al.2 citations
Major depressive disorder (MDD) and posttraumatic stress disorder (PTSD) are debilitating psychiatric conditions associated with poor health outcomes similarly observed in non-pathological aging. Ketamine is a dissociative anesthetic and NMDA receptor antagonist with demonstrated rapid reduction in symptoms associated with Treatment Resistant Depression (TRD) and PTSD. Ketamine's effects on...
Background: Treatment-resistant depression (TRD) affects up to a third of patients with major depressive disorder and remains difficult to manage with conventional therapies. Rapid-acting antidepressants targeting the glutamatergic system, such as ketamine, esketamine, and dextromethorphan-bupropion, have emerged as promising alternatives. Nitrous oxide, also an NMDA receptor antagonist, has...
BACKGROUND: Over the past ten years, several psychedelic compounds, including tryptamines like lysergic acid diethylamide/LSD, psilocybin, ayahuasca, and dimethyltryptamine/DMT, have been tested in clinical trials for a range of psychiatric conditions, such as anxiety and depression. While these compounds are relatively available for treatment, ketamine and its S(+) enantiomer, esketamine, are...
Research SquareOctober 30, 2025Elisabeth Kenne Sarenmalm, Salmir Nasic, Anna-Lena Emanuelsson Loft et al.
preprint
Abstract Purpose This 5-year longitudinal randomized controlled trial explored the long-term efficacy of a MBSR intervention for psychological and biological response in breast cancer survivors. Methods A total of 166 women were randomly assigned into one of 3 groups: MBSR, Active controls and non-MBSR. Data were collected at baseline, 3-months, 6-months and 1-year follow-up, thereafter yearly...
INTRODUCTION: Functional impairment is commonly reported amongst individuals with major depressive disorder (MDD) or treatment-resistant depression (TRD). Extant evidence suggests that ketamine and esketamine, N-methyl-D-aspartate (NMDA) receptor antagonists and glutamatergic modulators, have shown efficacy in treating MDD/TRD. While symptom reduction remains central to treatment, many...
Background: Comorbid depressive symptoms are prevalent in patients with breast cancer, which adversely impacts postoperative recovery outcomes. Esketamine has emerged as a promising intervention for perioperative depression due to its rapid and sustained effects. This study aims to investigate the impact of the continuous intravenous infusion of esketamine during the perioperative period on...
Background Ketamine and esketamine have demonstrated rapid, short-term antidepressant effects in major depressive disorder (MDD), but their relative safety remains unclear. This review aims to update the evidence on the safety of two agents for MDD and indirectly compare their safety and tolerability. Method We systematically searched PubMed, PsycINFO, Embase, and Cochrane databases up to 1 May...
Psilocybin is a serotonergic psychedelic with growing evidence for efficacy in mood disorders, and its therapeutic potential in obsessive—compulsive disorder (OCD) and related conditions is increasingly recognised but remains understudied. We systematically evaluated clinical and preclinical evidence on psilocybin's effects on obsessive and compulsive behaviours with attention to translational...
Background: Depression is a common complication of Parkinson disease (PD). This study investigated whether a single dose of esketamine could alleviate depressive symptoms in an MPTP mouse model by activating G protein-coupled receptor 109 A (GPR109A) and reducing neuroinflammation. Methods: Adult male C57BL/6 J mice (8 weeks, 25–30 g) were allocated into three groups: saline,...
PsychopharmacologyOctober 27, 2025Nina Gregoire, Ethan Klukas, Kimberley Kaseweter et al.
Ketamine-assisted therapy is emerging as a fast-acting intervention for treatment-resistant depression and anxiety. However, individual response to treatment varies, and little is known about how personality traits and trauma history influence outcomes. This study investigated whether distinct personality profiles emerge in a real-world sample of patients undergoing ketamine therapy and...
Anxiety and depressive disorders affect hundreds of millions globally, with substantial barriers limiting access to evidence-based treatments like cognitive behavioral therapy. Digital mental health interventions offer potential solutions to improve access to support. However, evidence of efficacy through randomized controlled trials is essential for clinical adoption. This study evaluated the...
More than 280 million individuals worldwide suffer from depression, which is one of the main causes of mental disability. It has multiple subtypes, and conventional treatments have limitations such as slow onset of action, high non-response rate, and numerous side effects. For instance, it takes two to six weeks for selective serotonin reuptake inhibitors (SSRIs) to start working, and about 30%...